Skip to main content

Viral Hepatitis: Hepatitis B (& D)

  • Chapter
  • First Online:
Book cover Liver Disorders

Abstract

The field of viral hepatitis including that of hepatitis B is rapidly evolving. There continues to be an explosion of new information not only on treatment options but also on management of those with acute and/or chronic hepatitis B. In light of this, the focus of this chapter is not on addressing information typically in textbooks of hepatology but rather on a framework of specific patient management questions which may be faced by the provider in the care of the patient affected by hepatitis B infection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lada O, Benhamou Y, Poynard T, Thibault V. Coexistance of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of “a” determinant variants. J Virol. 2006;80(6):2968–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Galati G, Vincentis A, Vespasiani-Gentilucci U, Gallo P, Vincenti D, Solmone M, et al. Coexistance of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination. BMC Gastroenterol. 2014;14(94):1–4.

    Google Scholar 

  3. Colson P, Borentain P, Motte A, Henry M, Moal V, Botta-Fridlund D, et al. Clinical and virological significance of the co-existance of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology. 2007;367:30–40.

    Article  CAS  PubMed  Google Scholar 

  4. Hoofnagle J, Doo E, Liang J, Fleischer R, Lok A. Management of hepatitis B; summary of clinical research workshop. Hepatology. 2007;45(4):1056–75.

    Article  CAS  PubMed  Google Scholar 

  5. Reddy K, Beavers K, Hammond S, Lim J, Falck-Ytter Y. American Gastroenterological Association Institute Guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppresive drug therapy. Gastroenterology. 2015;148(1):215–9.

    Article  CAS  PubMed  Google Scholar 

  6. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521–30.

    Article  PubMed  Google Scholar 

  7. LeFevre M. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventative Services Task Force Recommendation Statement. Ann Intern Med. 2014;161(1):58–67.

    Article  PubMed  Google Scholar 

  8. Maruyama T, Schodel F, Iino S, Koike K, Yasuda K, Peterson D, et al. Distinguishing between acute and symptomatic chronic hepatitis B virus infection. Hepatology. 1988;8(4):766–70.

    Article  Google Scholar 

  9. Draelos M, Morgan T, Schifman R, Sampliner R. Significance of isolated antibody to hepatits B core antigen determined by immune response to hepatitis B vaccination. JAMA. 1987;258(9):1193–5.

    Article  CAS  PubMed  Google Scholar 

  10. Al-Mekhaizeem K, Miriello M, Sherker A. The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. Can Med Assoc J. 2001;165(8):1063–4.

    CAS  Google Scholar 

  11. Lok A, McMahon J. AASLD practice guidelines: chronic hepatitis B. Hepatology. 2007;45(2):507–39.

    Article  CAS  PubMed  Google Scholar 

  12. Al-Mahtab M, Rahman S, Akbar S, Kamal M, Khan M. Clinical use of liver biopsy for the diagnosis and management of inactive and aymptomatic hepatitis B virus carriers in Bangladesh. J Med Virol. 2010;82:1350–4.

    Article  PubMed  Google Scholar 

  13. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.

    Article  PubMed  Google Scholar 

  14. Mast E, Weinbaum C, Fiore A, Alter M, Bell B, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR. 2006;54(RR16):1–23.

    Google Scholar 

  15. Sarkar M, Terrault N. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology. 2014;60(2):448–51.

    Article  PubMed  Google Scholar 

  16. Reddy K, Pavri T. Long-term safety of HBV therapies and when to stop therapy. Crit Issues HBV. 2014;1(1):17–9.

    Google Scholar 

  17. Sorrell M, Belongia E, Costa J, Gareen I, Grem J, Inadomi J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150(2):104–10.

    Article  PubMed  Google Scholar 

  18. Chu C, Liaw Y. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26(2):142–52.

    Article  CAS  PubMed  Google Scholar 

  19. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98–107.

    Article  CAS  PubMed  Google Scholar 

  20. Keefe E, Dieterich D, Han S, Jacobson I, Martin P, Schiff E, et al. A treatment algoright for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2(2):87–106.

    Article  Google Scholar 

  21. Wong R, Gish R. Implementing best practices when initiating hepatitis B virus therapy. Crit Issues HBV. 2014;1(1):5–10.

    Google Scholar 

  22. Lau D, Javaid A. Evaluating underlying causes of HBV treatment failure. Crit Issues HBV. 2014;1(1):13–5.

    Google Scholar 

  23. Lok A, McMajon B. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.

    Article  PubMed  Google Scholar 

  24. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53(3):449.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Venelin Kounev M.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Taranukha, T., Kounev, V. (2017). Viral Hepatitis: Hepatitis B (& D). In: Saeian, K., Shaker, R. (eds) Liver Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-30103-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30103-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30101-3

  • Online ISBN: 978-3-319-30103-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics